TapImmune (NASDAQ:MRKR) Stock Price Down 27.2%

TapImmune Inc. (NASDAQ:MRKR)’s stock price was down 27.2% on Friday . The stock traded as low as $6.15 and last traded at $6.33, approximately 3,447,418 shares changed hands during mid-day trading. An increase of 656% from the average daily volume of 455,912 shares. The stock had previously closed at $8.70.

Several equities analysts recently weighed in on MRKR shares. ValuEngine raised shares of YY from a “sell” rating to a “hold” rating in a research note on Friday, June 7th. Oppenheimer set a $32.00 target price on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Wednesday, July 3rd. WBB Securities raised shares of TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 target price for the company in a research note on Friday, March 29th. Roth Capital raised shares of Himax Technologies from a “neutral” rating to a “buy” rating and raised their target price for the company from $4.00 to $5.00 in a research note on Thursday, May 30th. Finally, Zacks Investment Research cut shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $10.21.

The business’s fifty day simple moving average is $7.21. The firm has a market capitalization of $396.17 million, a price-to-earnings ratio of -3.79 and a beta of 0.34. The company has a current ratio of 19.73, a quick ratio of 19.73 and a debt-to-equity ratio of 0.01.

TapImmune (NASDAQ:MRKR) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. On average, research analysts anticipate that TapImmune Inc. will post -0.51 earnings per share for the current year.

A hedge fund recently raised its stake in TapImmune stock. Riggs Asset Managment Co. Inc. raised its holdings in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,919 shares of the company’s stock after purchasing an additional 18,650 shares during the quarter. Riggs Asset Managment Co. Inc. owned approximately 0.10% of TapImmune worth $303,000 at the end of the most recent reporting period. 33.64% of the stock is currently owned by hedge funds and other institutional investors.

About TapImmune (NASDAQ:MRKR)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Read More: How does a reverse stock split work?

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.